Procoagulant molecular decoy for treating hemophilia A or B with or without inhibitor

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9493761
APP PUB NO 20140050716A1
SERIAL NO

14002253

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a pharmaceutical composition including a modified factor Xa (GDXa), said modified GDXa being nonthrombogenic, able to bind to TFPI but not able to bind to phospholipids, for preventing or treating a hemorrhagic accident in a patient with hemophilia A or B with or without inhibitor.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
UNIVERSITE GRENOBLE ALPESSAINT-MARTIN-D'HÈRES

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Polack, Benoit Saint Martin le Vinoux, FR 4 36
Thomas, Aline Meylan, FR 4 10

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 15, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00